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ABSTRACT : For the purpose of clarifying the defensive capacity of the 
tumor-bearing host against the tumor was evaluated from the standpoint of superoxide 
dismutase (SOD) activity in the peripheral blood of untreated gastric cancer patients as 
compared with clinicopathologic factors. There was not significant difference in SOD 
activity between the entire gastric cancer patients and normal subjects. In contrast, a 
significant difference in SOD in monocytes (MNC) and polynuclear leucocytes (PMN) was 
found between early and advanced gastric cancer patients. SOD activities in advanced 
gastric cancer patients were obviously depressed. According to the disease stage, those 
in Stage IV patients were also apparently reduced when compared to reduction of 
superoxide dismutase (SOD) activity in MNC was observed in patients with hepatic 
metastasis (p<0.05) and that in MNC and PMN was seen in patients with peritoneal 
dissemination (p<0.01). As for gross findings by Borrmann' classification, Borrmann IV 
gastric cancer revealed significantly reduced SOD activity in MNC and PMN (p<0.01). 
 It is concluded that SOD activity in the peripheral blood was depressed in accordance 
with advanding cancer stage. On the in vitro basic study to clarify the mechanism on 
SOD activity in gastric cancer patients it was certified that there was no influence of 
extracellular factors such as serum factor obtained from cancer-bearing patients, cultured 
cells, immunodepressant factor and nutrients on SOD activity. In contrast, intracellular 
factor of inhibitors of RNA and protein synthesis induced by adriamycin, actinomycin 
puromycin was greatly responsible for SOD activity in cultured cells. 
 However, the inhibition of DNA synthesis could be not entirely neglected. It is dubious 
in association with inhibition of DNA synthesis. 
 It was warned that the use of chemotherrapy of adriamycin and actinomycin D 
contributed to reduced SOD activity for the treatment of advanced cancers such as stage 
IV and Borrmann IV gastric cancers.
       INTRODUCTION 
 Since superoxide dismutase was discoverd in 
1969 by McCord and Friduvitch' ) as an enzym 
to uniformly dissolve superoxide to oxygen 
and superoxide oxidor, it has become well 
known in living cells. In mammalian, two kinds 
of SOD, Cu, Zn-sensitive SOD in cytoplasma 
and Mn-sensitive SOD in mitochondria, were
identified"). Recently a presence of very small 
amount of EC-SOD also was recognized by 
Marklund4'. 
 To date, clinical application of SOD has 
become prevalent in the field of inflammation, 
carcinogenesis degenerative process, ARDS, 
irradiation injury, chromosome abnormality, 
ischemia, reperfusion syndrome') and so on. 
 With respect to SOD in tumor cells, since 
Yamanaka') reported disappearance and/or
absence of Mn-SOD in carcinogenetic process 
in VI-38 cells by SV40, the study on SOD has 
been performed in cultured cells and experi-
mentally implanted cells. 
 It is clarified that the majority of cancer cells 
in Morris hepatoma 39244 (Dionisi9), Ehrlich 
ascitic liver cancer cells, H6 hepatoma (Oberley), 
CH3 breast cancer cells") represent a decrease 
in total SOD, marked reduction of disapperance 
of Mn-SOD activity. In the human, a decrease 
in SOD activity in non-cancer tissues was 
observed in cases of renal cell carcinoma by 
Westmann14) and lung cancer by Hartz'51. A few 
reports concerning sequential study on SOD 
activity with advancing cancer are now avail-
able. It corresponds only to an experimental 
study on Yoshida' sarcoma by Sakuma'), It is 
clarified that reduction of Cu, Zn-SOD activity is 
more remarkable in late stage rather than in 
early stage in the liver, heart, brain and lung. 
 On the basis of the fact") that the levels of 
SOD activity in tissues proportionate to those 
in the blood, this study dealt with changes in 
total SOD and Mn-SOD activities in RBC, PMN 
and MNC in combination with the effect of 
anticancer agents on blood corpscules.
    MATERIAL AND METHOD 
1. Clinical evaluation 
 Fourty-four preoperative gastric cancer pa-
tients were eligible for this study. Sex distri-
bution of men to women was 29:15. The ages 
ranged from 38 to 79 with an average of 62.5 
years old. As a control, 39 healthy subjects were 
selected. 
 SOD activities in MNC, PMN and RBC 
obtained from untreated patients and healthy 
candidates were measured and compared to the 
clinicopathologic factors. 
2. Basic evaluation 
 In vivo study was made on cultured lympho-
cytes in 10% FBS to make clear of changes in 
SOD activity of tumor-bearing host. 
1. Evaluation of extracellular factor 
Experiment 
1) mixed culture with human cultured cancer 
cells and lymphocytes 
 HeLa cells were used for the evaluation. 
Changes in SOD activity were observed in
admixture of HeLa cell to 10 times leucocytes 
for 72 hours. 
2) lymphocytes culture with the serum from 
cancer patients 
 SOD activity in leucocytes was compared with 
before and after culture with the use of the 
serum from colon cancer patients for 72 hours. 
3) lymphocyte culture in addition to acid soluble 
glycoprotein (ASP) 
 The effects of ASP on SOD activity in cultered 
lymphocytes were evaluated at the concen-
trations of 125, 250 and 500mg/dl. ASP was 
supplied from Otsuka Assay Co, which was one 
of immunosuppressive proteins. 
4) The effects of different concentrations of 
glucose on cultured lymphocytes. 
 The lymphocytes from healthy subjects 
humans were cultured in RPMI without glucose, 
and adding 100, 200, 400mg/dl glucose for 72 
hours. 
5) The effects of different concentrations of FBS 
on cultured lymphocytes 
 SOD activity in cultured lymphocyte was 
measured at 1, 5, 10% concentrations of FBS in 
RPMI. 
2. Evaluation of intracellular factors 
1) Blastogenesis of lymphocytes stimulated by 
PHA. SOD activity was observed at the time 
of lymphocyte blastogenesis stimulated by 
PHA-P. And also nuclear DNA and RNA con-
tents were measured by using flow cytometry 
according to Darzynkiewicz and Tagawa' me-
thod. 1s, 19) 
2) The effect of inhibitors of protein synthesis 
on SOD activity 
 The lymphocytes were cultured with DNA 
synthesis inhibitors (cisplatinum 10,ug/ml), 
(mitomycin C 1.0ug/ml), adriamycin 0.5ug/ml, 
RNA synthesis inhibitor (actinamycin D 0.lpg/ 
ml), protein synthesis inhibitor (puromycin 
1.0ug/ml), which concentrations were set up at 
the cytostatic concentration against the tumor 
cells. 
Method 
 SOD activity was measured according to the 
method reported by McCord and Fridovich' ). 
Inhibition of cytochrom deoxidized reaction 
were estimated by using spectrometry (Hidachi 
Model 557) at 25CC in reflection of changes 
in cytochrom reduction in accordance with
superoxide production. Inhibitory rates of cyto-
chrom reduction were calculated as reported by 
Kobayashiz") as one unit of 50% SOD inhibition. 
SOD activity in PMN, MNC and RBC were 
expressed as per blood corpuscles. 
 SOD activity in mitochondria also was 
measured by the addition of 1mM KCN. The 
values averaged and t-test was used for 
estimation of statistic difference of the average 
values.
          RESULTS 
Clinical evaluation 
 SOD activity in gastric cancer patients aver-
aged 48.0±10.1,a/108 in RBC, 8.8±2.4u/10' in PMN 
and MnSOD activities were 1.4±0.6,u/10' as a 
whole, 25.6±9.9y in MNC 2.8±1.4u/10' in 
MnSOD. There was not significant difference 
between healthy and gastric cancer patients 
(Table 1) and between both sexes. 
2. SOD activity in blood corpuscles between 
early and advanced gastric cancer patients. 
 Although there was not significantly different 
in RBC, significant difference was seen in PMN. 
In advanced cases, it was depressed (p<0.01) 
SOD activity in MNC in advanced patients was
23.1±6.7 on the average in contrast with 28.5± 
9.4,u/10' which was significantly depressed as 
compared to 28.3±11.5,u/10' early gastric cancer 
(Fig. 1). 
3. SOD activity and gross finding of gastric 
cancer. 
 Total SOD activities in PMN, MNC, and whole 
blood were significantly suppressed in Bo-
rrmann IV gastric cancer patients (p<0.01) (Fig. 
2). Only SOD in MNC in Borrmann II and III 
gastric cancer was reduced. 
4. Disease stage of gastric cancer 
 SOD activity in whole blood corpuscles was 
depressed with advances in the disease stage 
although that in Stage II somewhat increased. 
In ly (+) gastric cancer, SOD activities in PMN 
were appearently reduced as compared to those 
in ly (-). This tendency in v (+) gastric cancer 
was similar to ly (+). 
Basic evaluation 
(1) Mixed culture with human tumor cells and 
lymphocytes 
 In mixed culture with HeLa cells and 10 
human lymphocytes, proliferation of HeLa cells 
was not inhibited and no alternation of lympho-
cytes in MLTR noted (Fig. 4). There was not 
remarkable changes in SOD in lymphocytes
Table 1. SOD activity of patients with gastric cancer and of normal controls
                      RBC" PMN2 ,u/1 x 10' MNC3' ,u/1 x 10' 
                  ,u/mgHg ,u/1 x 108 Total- Manganase Total- Manganase
 Gastric Cancer 17.9±4.8 48.0±10.1 8.8±2.4 1.4±0.6 25.6± 9.9 2.8±1.4 
       (n=44) 
Normal Controls 19.1±4.3 49.3±11.1 8.9±1.9 1.3±0.3 28.1± 9.5 3.1±1.0 
       (n=39) 
      Sex Male 18.3±4.0 47.4±12.6 8.2±1.6 1.2±0.3 28.0± 9.7 3.2±1.1 
       (n=24) 
       Female 19.1±6.0 49.3±12.5 9.6±2.3 1.4±0.3 28.6± 9.8 3.1±0.7 
       (n = 15) 
      Age 20- 23.0±4.2 64.4± 5.0 9.1±1.3 1.2±0.2 27.6±13.3 3.3±1.1 
   (yr) (n= 5) 
          30--- 18.7±4.2 45.3±10.9 8.9±2.2 1.4±0.3 29.4± 7.9 3.4±1.0 
       (n = 17) 
          50- 18.6±4.0 .50.3±11.1 8.1±2.2 1.2±0.4 24.9± 7.8 2.6±0.9 
       (n = 10) 
          70- 18.3±4.9 48.8± 7.5 9.1±1.7 1.1±0.2 30.0±14.1 3.2±0.9 
       (n = 7) 
 1) RBC : erythrocytes 
 2) PMN : polymorphonuclear leukocytes 
 3) MNC : mononuclear leukocytes
Table 2. SOD activity of peripheral blood cells in gastric cancer 
        patients and P, N, H, PS factors 
               RBC PMN (total) MNC (total) 
              (u/mgHb) u/10' cells u/10' cells
P (-) (34) 18.7±4.8 9.2±2.3 26.4±9.7 
P (+) (6) 13.8±2.0 * 6.5±0.9 * 18.4±6.4 
N (-) (24) 17.2±3.6 9.3±2.6 27.1±10.5 
N (+) (19) 18.9±6.0 8.4±2.0 23.3±8.3 
H (-) (40) 18.0±5.0 8.9±2.4 26.0±9.8 
H (+) ( 2) 18.0±5.2 7.6±1.0 17.5±2.6 
PS (-) (31) 18.3±5.0 9.3±2.4 27.2±10.1 
PS (+) (12) 17.2±4.6 7.9±2.0 20.2±6.6 
                                        * P<0.01
                                       * * p <0.05
Fig. 1. SOD activity of peripheral blood cells 
       between early and advanced cases in gastric 
       cancer patients
Fig. 3. SOD activity of peripheral blood cells in each 
      stage in gastric cancer patients
Fig. 2. SOD activity of peripheral blood cells class-
      fied by Borrmann types
between MLTR and control groups. Fig. 5 
showed changes in SOD activity in the serum 
taken from the patients with colon cancer, which 
contained 714u/ml IAP. SOD activities were 
depressed as being 14.3,u/ 10' in total-SOD and 
0.8u/10' in Mn-SOD. However, there was not
Fig. 4. Mixed Lymphocytes Tumor Reaction for 72 
       hours
Fig. 5. SOD activity of healthy volunteers' lympho-
      ctes after 72 hour incubation with serum of 
       advanced cancer patient
activity 
 There was not remarkable change in SOD 
activity between with and without the addition 
of each concentration of ASP to culture medium 
as shown in Fig. 6 in comparison with the 
control, which did not contain ASP and was 
regarded as being 100%. 
4. The effect of different concentrations of 
glucose in culture medium on SOD activity. 
 It aimed at the effect of different blood sugar 
levels in patients on SOD activity. Fig. 7 showed 
that the higher the concentration of glucose, the 
greater Cu-Zn SOD activity and the lesser, 
Mn-SOD had become. There was not satistically 
significant difference in a total of SOD activity 
between with and without the addition of glu-
cose. 
5. The effect of lymphocyte culture at different 
concentrations of FBS 
 With advancing the disease stage, the nutri-
tional condition of a tumor-bearing host has 
become aggravated. In carcinomas of the 
digestive tract, poorly nutrionatal condition is 
in proportion to progression of the tumor. The 
effect of poor nutrition on SOD activity was 
tested at different FBS concentrations. There 
was not statistically significant difference in 
total and Cu Au SOD activities between different 
concentration of 5% and 1% as compared with 
the control of a value of SOD activity in 10% 
FBS, which was regarded as 100% (Fig. 8).
Fig. 6. SOD activity of healthy volunteers' lympho-
      ctes after 72 hour incubation with various 
          ASP rnnr'ntratinn
significant difference in SOD activity between 
healthy and patient's sera. 
3. The effect of the addition of ASP on SOD
Fig. 7. SOD activity of healthy volunteers' lympho-
      ctes after 72 hour incubation with various 
       glucose concentration
Fig. 8. SOD activity of healthy volunteers' lympho-
      cytes after 72 hour incubation with various 
      FBS concentration
Fig. 9. Relationship between SOD activity and RNA 
      peak channel (RNA contents) in PHA-P 
      stimulated lymphocytes (n=3)
Fig. 10. SOD activity of lymphoctes for 2 hour 
      exposure to agents following 72 hour 
      incubation
2. Intracellular factor 
1) lymphoblastogenesis by stimulation with 
PHA-P 
 SOD activity stimulated by PHA-A in lym-
phocytes increased with elapse of time and it 
reached to 3.7 times as high as prior values after 
72 hours (Fig. 9). RNA contents also rose 1.4 
times after 48 hours and 1.97 times after 72 
hours. 
2) The effect of anticancer agents and protein 
synthesis inhibitor on lymphocyte culture. 
 SOD activity in lymphocytes in contact with 
CDDP and MMC of protein synthesis inhibitor 
increased 1.43 and 1.25 times as compared with 
the control. On the other hand, in case of ADM 
it dereased 1.92 times. in contact with 
actinomycin-D, it reduced to 62%, Meanwhile, in 
case of puromycin, inhibitor of portein 
synthesis, it was decreased to 60%.
         DISCUSSION 
 It is assumed that SOD activity is indispen-
sable for action as scavenger of free radical 
produced in body as already reported in gastric 
cancer by NakagoeL3>. In this series, SOD 
activity in RBC, MN and MNC had become 
reduced with advances in disease stage. 
Furthermore, in advanced cancer patients with 
peritoneal dissemination, hepatic metastasis as 
well as ly (+) v (+), it was apparently inhibited. 
 In malignant diseases, many researchers 
reported reduced SOD activities, for example, 
SOD in MN in malignant lymphoma, Mn-SOD 
in lymphocytes in breast cancer as reported by 
Michelson"4>. SOD in RBC in 11 malignant 
lymphomas in spite of no change in SOD of RBC 
of lung cancers by Saito25'. Sato26> also in-
vestigated Cu-Zn SOD and Mn-SOD activities 
in sera and lymphocytes obtained from patients 
with malignant diseases by using polyclonal 
antibodies. Consequently he reported high 
Cu-Zn SOD and Mn SOD activities in sera and 
lymphocytes irrespective of the kinds of malig-
nant diseases. It seemed that this discrepancy 
would be based on the differences in measure-
ment method which might be associated with 
the differences between enzym-action and 
antigen-presenting sites. 
 From above results, it is suggestive that SOD
molecules be not reduced in accordance with 
progression of the tumors but the molecules 
have become inactive because of most of 
inactive molecules and/or because of the 
surrounding circumstances to make them 
inactivated. 
 It is well known that diethyl dithiocarba-
mate (DDC)27) inhibits SOD activity and also 
thiocurbanyl acid makes Cu-Zn-SOD activities 
inactive in spite of no evidence of their presence 
in humans. It is also accepted that SOD activity 
in RBC is inhibited in cupper dificiency.L3> 
However, recovery to 60% Cu level in RBC made 
it possible to revert to the normal SOD activity. 
 In this series, it was certified that reduced 
SOD activity in advanced cancer patients was 
not in association with Cu deficiency because 
of normal levels of Cu in sera. 
 Okahatake29> reported that T lymphocytes had 
higher SOD activity rather than B lymphocytes. 
In this series, lymphocyte fractions did not show 
remarkable variations between early and 
advanced cancer patients. In this study, there 
was not significant difference in leucocyte 
fraction except that OKIal fraction somewhat 
increased in advanced cancer patients. In this 
series, SOD activity in lymphocytes was not 
altered in culture medium which added sera 
from healthy human and cancer patient's and/ 
of the addition of ASP, immunosuppressive 
protein. 
 Kasemset and Oberly30> clarified that SOD 
activity in the myocardium was reduced by 
adding glucose into the peritoneal cavity in mice, 
in particular Mn-SOD activity was much more 
inhibited in reflection of inhibition of super-
oxide production, followed by inhibited Mn-SOD 
activity. There was not influenced on SOD activ-
ity in lymphocytes by differenct concentra-
tions of FBS in culture medium. 
 In this series, it was certified that activated 
SOD activity was contributary for an increase 
of RNA content. In contrast, DNA inhibition 
by MMC, ADM, CDDP led to increased SOD 
activity. It is accepted the reasons are that 
MMC causes damage to nucleoic acid by 
production of OH- with help of a small amount 
of metal. On the other hand, it converts to 
semiquinone type which produes O2- by action 
of NADPH-P450 reductase31 >. And also CDDP
contributes to production of 02- H2O2 from 
macrophages >2>. High SOD activities imply 
induction of SOD by O-. In contrast, it is 
different in case of ADM with which SOD is not 
easy to be induced 33>. RNA synthesis inhibitor 
reduced SOD activity to 60% of the previous 
level. It is substantiated that SOD activity is 
closely associated with RNA synthesis. Niwa17> 
clarified that in comparative study on SOD in 
RBC, WBC platelets in patients with various 
cancers, SOD and 01 (Oi/SOD oxygen interme-
diate) did not remarkably vary and he contem-
plated that in early stage of carcinomas, excess 
01 might be generated by phagocytic cells as 
a result of enhanced defensive ability, thereafter, 
with progression of the tumor, 01 production 
would be inhibited because of depressed 
viability of phagocytes. His suggestion is 
consistent with the result in this study. As 
reported by Nakagoe23>, it is reliable to consider 
that depressed SOD activity is due to nothing 
to induce SOD or difficulty in induction of 
SOD. It is known that dose effects of Cu-Zn 
SOD exist in chromosome 21. On the other hand, 
Feaster34> explained that Cu--Zn SOD activity in 
Down' disease (21 trisomy) was 1.5 times as high 
as the normal in RBC, and fibroblasts in 
reflection of gene dose effect. Joenje35) reported 
that repair process from damage to chromosome 
was impaired by high concentration of O2-
which was caused by depressed SOD activity 
in patients with Fanconi anemia. On the 
contrary, Yoshimitsu36> insisted that abnormal-
ity of chromosome might result in depressed 
SOD activity. 
 On the basis of a result of this study on SOD 
activity in advanced cancer patients, it is 
interest to emphasize that anticancer agents 
produce inhibited SOD activity in addition to 
a low SOD activity seen in tumor-bearing hosts. 
Recent studies focus on the use of L-SOD which 
makes up for too short half-life time of SOD 
and makes it possible to penetrate into the 
inside of cells, and also to explore drugs of free 
radical scavenger. 
 In conclusion, this study on SOD activity in 
advanced cancer patients warned of the treat-
ment of anticancer drugs and radiation.
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